
Key Capital COVID-19 Oral Pill Vaccine Records 90% Reduction in Virus Infectivity in Early Study
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
Promising Safety Profile and 90% Reduction in Virus Infectivity Reported for Key Capital COVID-19 Oral Pill Therapeutic Vaccine
NEW YORK, NY, January 6, 2021 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that it is fast becoming clear that the approach to global COVID-19 vaccination is in crisis.
Key Capital Invites Partnering Inquiries for COVID-19 Therapeutic Vaccine.
New York, NY December 1, 2020 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that in association with Immunitor Inc, the Company will seek to fast-track further clinical studies and regulatory approval of the FDA Orphan Drug Designated Immunitor V5 as a development priority.
New York, NY November 23, 2020 – KEY CAPITAL CORPORATION (OTC Pink: KCPC) advises that Key Biotec, a division of Key Capital, has entered into agreement with Immunitor group interests (“Immunitor”) to exclusively license its breakthrough patented oral tableted immunotherapeutics platform products for North, Central and South America (excluding Canada), the EU (excluding UK), Australia and New Zealand (the “Territory”).